Ibio
Yahoo Finance • last year
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas and SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIR... Full story
Yahoo Finance • last year
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
– Board appointments solidify management team to lead iBio’s AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precis... Full story
Yahoo Finance • last year
iBio Forges Research Collaboration with the National Institutes of Health
iBio, Inc. – NIH to evaluate iBio’s patented AI-driven epitope steering platform for Lassa fever vaccine development – BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI... Full story
Yahoo Finance • 2 years ago
iBio Accelerates Transformation to AI-Powered Biotech
– Divesting CDMO business and cGMP biologics manufacturing facility – – Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform – – Restructuring measures to result in ~50% annualized cost savings – BRYAN, T... Full story
Yahoo Finance • 3 years ago
iBio to Participate in the H.C. Wainwright Global Investment Conference
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today ann... Full story
Yahoo Finance • 3 years ago
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
iBio, Inc. BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announ... Full story
Yahoo Finance • 3 years ago
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming®Manufacturing System, announced today a poster pr... Full story
Yahoo Finance • 3 years ago
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Comp... Full story
